Infectious Diseases News and Research

RSS

Intestinal parasites significantly reduce immune response to the cholera toxin

Cholera patients also infected with parasitic intestinal worms have a significantly reduced immune response to the cholera toxin, according to a report published March 31st in the open-access journal PLoS Neglected Tropical Diseases.

30 Mar 2009

Intercell receives FDA approval of IXIARO, novel vaccine for Japanese encephalitis

Intercell AG (VSE: ICLL) today announced that the U.S. Food and Drug Administration (FDA) approved IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE).

30 Mar 2009

New York Times examines challenges faced by a Minneapolis hospital that treats many Somali, Hispanic patients

The New York Times on Sunday profiled the Hennepin County Medical Center, a Minneapolis-based hospital that "offers an extraordinary vantage point on the ways immigrants are testing the American medical establishment."

30 Mar 2009

AP/Google.com examines efforts to address drug-resistant tuberculosis in China, other countries

The AP/Google.com on Monday examined efforts to prevent and control the spread of drug-resistant tuberculosis in China and other countries.

30 Mar 2009

Cepheid announces new TB test for use in developing countries

The Sunnyvale, Calif.-based company Cepheid on Tuesday announced it has developed a rapid diagnostic test for tuberculosis that it will sell at a reduced cost in developing countries, the San Francisco Chronicle reports. The test was developed in partnership with the Foundation for Innovative New Diagnostics, the University of Medicine and Dentistry of New Jersey, and the National Institute of Allergy and Infectious Diseases.

30 Mar 2009

Discovery of tuberculosis bacterium enzyme paves way for new TB drugs

A team of University of Maryland scientists has paved the way for the development of new drug therapies to combat active and asymptomatic (latent) tuberculosis infections by characterizing the unique structure and mechanism of an enzyme in M. tuberculosis, the bacterium that causes the disease.

29 Mar 2009

Discovery of protein that reactivates latent herpes simplex virus

Research in Public Library of Science (PLoS) Pathogens appears to solve a long standing medical mystery by identifying a viral protein, VP16, as the molecular key that prompts herpes simplex virus (HSV) to exit latency and cause recurrent disease.

29 Mar 2009

New discovery could lead to new methods to block the transmission of HIV

A team of researchers at Mount Sinai School of Medicine and the UC Davis Center for Biophotonics Science and Technology have for the first time captured on video the transfer of human immunodeficiency virus (HIV) from infected to uninfected T cells through structures called virological synapses.

29 Mar 2009

Male circumcision reduces risk of herpes simplex virus type 2 and human papillomavirus

Heterosexual men who undergo medical circumcision can significantly reduce their risk of acquiring two common sexually transmitted infections - herpes simplex virus type 2 (HSV-2), the cause of genital herpes, and human papillomavirus (HPV), which can cause cancer and genital warts, according to a report in the March 26 issue of the New England Journal of Medicine (NEJM).

26 Mar 2009

Rockefeller neuroscientist applies basic science to health care reform

A self-described "molecular sociologist" is extending his basic research to the national policy debate on health care reform. Bruce McEwen, head of the Laboratory of Neuroendocrinology, led a panel of scientific experts last month at the Institute of Medicine's Summit on Integrative Medicine and the Health of the Public. The Institute is the most prominent independent medical advisory board in the country and will release a report from the conference in November, as Congress is likely to be considering major health care legislation.

25 Mar 2009

FDA approves new indication for Wyeth's Tygacil (tigecycline)

Wyeth Pharmaceuticals, a division of Wyeth has announced that the U.S. Food and Drug Administration (FDA) approved Tygacil (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens.

24 Mar 2009

U.S., South African scientists launch $60 million HIV/TB research initiative

Scientists from the U.S. Howard Hughes Medical Institute and South Africa's University of KwaZulu Natal on Wednesday announced the launch of a $60 million, 10-year initiative to establish a new research facility to examine the associations between HIV and tuberculosis, the Boston Globe reports.

23 Mar 2009

Carbohydrate-based medicine

Scientists from Germany today reported a major advance toward opening the doors of a carbohydrate-based medicine chest for the 21st Century.

22 Mar 2009

Cathepsin B increases apoptosis in fulminant hepatic failure

The traditional view is that hepatocyte necrosis is the main feature of fulminant hepatic failure, but increasing evidence implicates a dominant role for hepatocyte apoptosis in this pathogenesis.

22 Mar 2009

New TB vaccine developed using a genetically modified adenovirus

McMaster University researchers are about to launch Canada's first tuberculosis (TB) vaccine clinical trial with a vaccine totally designed, manufactured and tested within McMaster.

20 Mar 2009

Study finds extensive patient sharing among hospitals; could impact spread of infectious diseases

Findings from the first in-depth study of patient sharing show that hospitals share large numbers of patients with other acute care facilities without knowing it.

20 Mar 2009

Cherries show promise in osteoarthritis pain relief

For the estimated 27 million Americans who suffer from osteoarthritis, pain relief may come with a cherry on top.

20 Mar 2009

Experimental vaccine shows promise in preventing cytomegalovirus infection

Each year, approximately 8,000 infants in the United States develop severe hearing, mental or movement impairments after becoming infected with cytomegalovirus (CMV), a common virus passed onto them while still in the womb.

19 Mar 2009

MRSA study suggests strategy shift needed to develop effective therapeutics

USA300-the major epidemic strain of methicillin-resistant Staphylococcus aureus (MRSA) causing severe infections in the United States during the past decade-inherits its destructiveness directly from a forefather strain of the bacterium called USA500 rather than randomly acquiring harmful genes from other MRSA strains.

17 Mar 2009

Alba Therapeutics announces next clinical trial of lead compound, Larazotide Acetate

Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate.

17 Mar 2009